GetTopicDetailResponse(id=b160551259f, topicName=抗PD-L1抗體, introduction=抗PD-L1抗體, content=null, image=null, comments=4, allHits=1077, url=https://h5.medsci.cn/topic?id=55125, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=64879, tagList=[TagDto(tagId=64879, tagName=抗PD-L1抗體)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1988691, encodeId=4a09198869102, content=<a href='/topic/show?id=b160551259f' target=_blank style='color:#2F92EE;'>#抗PD-L1抗體#</a>, objectTitle=Lancet Oncol：抗PD-L1抗體Avelumab是否可用于卵巢癌的一線治療？, objectType=article, longId=215475, objectId=8fb22154e583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fb22154e583, replyNumber=0, likeNumber=96, createdTime=2022-07-09, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fb22154e583, moduleTitle=Lancet Oncol：抗PD-L1抗體Avelumab是否可用于卵巢癌的一線治療？, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=8fb22154e583)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1988690, encodeId=f0381988690ed, content=<a href='/topic/show?id=b160551259f' target=_blank style='color:#2F92EE;'>#抗PD-L1抗體#</a>, objectTitle=Clin Cancer Res：新型抗PD-L1抗體LY3300054治療晚期實(shí)體瘤的療效和安全性, objectType=article, longId=206739, objectId=b029206e3989, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b029206e3989, replyNumber=0, likeNumber=97, createdTime=2021-08-21, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b029206e3989, moduleTitle=Clin Cancer Res：新型抗PD-L1抗體LY3300054治療晚期實(shí)體瘤的療效和安全性, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=b029206e3989)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1988689, encodeId=c18a1988689c7, content=<a href='/topic/show?id=b160551259f' target=_blank style='color:#2F92EE;'>#抗PD-L1抗體#</a>, objectTitle=2019 CSCO：抗PD-L1抗體CS1001治療MSI-H實(shí)體瘤有效性好、安全性高, objectType=article, longId=179912, objectId=89001e991243, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89001e991243, replyNumber=0, likeNumber=97, createdTime=2019-10-25, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89001e991243, moduleTitle=2019 CSCO：抗PD-L1抗體CS1001治療MSI-H實(shí)體瘤有效性好、安全性高, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=89001e991243)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1988688, encodeId=fdfa1988688b5, content=<a href='/topic/show?id=b160551259f' target=_blank style='color:#2F92EE;'>#抗PD-L1抗體#</a>, objectTitle=ASCO2019 |新型融合抗PD-L1抗體試用在中國(guó)晚期實(shí)體瘤患者中的應(yīng)用, objectType=article, longId=167544, objectId=773f16e5442b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=773f16e5442b, replyNumber=0, likeNumber=92, createdTime=2020-01-29, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=773f16e5442b, moduleTitle=ASCO2019 |新型融合抗PD-L1抗體試用在中國(guó)晚期實(shí)體瘤患者中的應(yīng)用, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=773f16e5442b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
